Close

Informa Markets in India all set to host the 9th edition of InnoPack Pharma Confex, virtually this year

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Optimizing Pouch Closure Performance through Advanced Sealant Layer Design

The pharmaceutical industry relies heavily on the physical integrity...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...
- Advertisement -

CPhI Conferences India, a division of Informa Markets in India, which hosts a number of successful pharmaceutical conferences, has announced the 9th Annual InnoPack Pharma Confex slated for 3rd and 4th September 2020, this year in a virtual format. This digital event will form a part of the Informa Markets in India’s Super September – Virtual B2B celebration. The initiative will cater to 5 key verticals, 5 coveted brands and 5 different communities all in one power booster month.

The Confex is the biggest platform for professionals from the Pharma packaging industry to congregate, network, exchange ideas and knowledge, form alliances and shape the future of the pharma packaging industry. The two day multi-track knowledge driven conference will bring together visionaries from various facets of the Pharma packaging business, and will comprise B2B networking, an Expo driven by Innovative Solutions, 6 Workshops, a Packaging Leaders Round Table session and the most celebrated India Packaging Awards in its 5th edition. The Confex will comprise over 50+ exhibitors, 100+ speakers & trainers and 100+ Nominations for the awards.

The Indian Pharmaceutical Industry is in the middle of big changes and not only the Industry is expected to accommodate Demographic, Epidemiological, and economic shifts in the world, but also has to upgrade manufacturing practices and match rigid standards from time to time in order to produce world-class medicines. The pharmaceutical packaging industry with a market size of USD 83.6 billion in 2019 is projected to reach 111.9 billion in 2024 with a CAGR of 6.0% between 2019 -2024. The growing use of oral drug delivery mode owing to patient compliance and convenience, increasing cases of communicable diseases, and the rise in the aging population in developed economies are responsible for the high share of the bottles segment. This growth is attributed to the increased demand for pharmaceutical packaging in pharma emerging economies such as BRIC (Brazil, Russia, India, and China) countries. Furthermore, trends towards safety, efficacy, and patient-friendly products are on the rise. Rising demand for advanced technology to address the increasing demand for routine injectable drugs to treat chronic conditions will boost the growth of the injectable drug delivery market over the coming years. The pharma packaging industry in India is evolving rapidly to adopt to changing policies and regulations in their markets as many Indian companies are now moving into the US and Europe.

Speaking on the announcement of the 9th edition of InnoPack Pharma Confex that will be held in a virtual format, Mr. Yogesh Mudras, Managing Director, Informa Markets in India, said, “InnoPack has a legacy of showcasing the best of pharma packaging solutions in terms of quality and design. It is also set to witness scintillating panel discussions by leading experts, this year in a virtual format with a pulse on the key trends and issues in the sector, while updating it in the latest innovations across the globe. The 2 day InnoPack Pharma Virtual Confex is as timely as it is relevant with the recent outbreak of COVID 19 during which the packaging manufacturers are facing supply chain disruption along with decreasing manufacturing at the site in many parts of the world. The Confex will ensure the continuous engagement through various networking activities and will discuss the ever – evolving challenges and solutions in pharmaceutical packaging.”

“We are extremely pleased to present the Innopack Confex as a part of the Informa Markets in India’s Super September – Virtual B2B celebration. With the lacuna that the Covid-19 situation has brought about, Informa Markets in India, drives its leadership vision and utilises its transformational digital platforms to serve the community and aid in rebuilding the economy,” he further added.

The scope and scale of this year’s event gets more bigger with increased number of participants, and workshops. This year the workshop will comprise topics such as Technologies for Anti – Covid Complaint Packaging Design and Patient Centric Packaging Designs, Sustainability and recycling Plastic for Packaging, Serialization & Cold Chain, and many focused topics with an underlying theme of conference being Embracing the new Era of Packaging as centre of driving business through disruptive innovations.

The sessions over the two-day conference will be delivered by Marcel De Grutter, PM Serialization & Liaison Regulatory & Government Affairs, Abbott; Chakravarthi AVPS, Global Ambassador, World Packaging Organisation; Sanjay Jain, President, Amneal Pharmaceuticals; Chandi Prasad Ravipati, General Manager, Aurobindo Pharma Limited; Dr. Pirthi Pal Singh, Head – Formulation Research & Development, Dr Reddy’s Laboratories; Rajesh Mishra, Head – Packaging Development, Abbott and amongst other key packaging experts. It will witness the E-presence of various Policy Makers, Industry Captains from Associations, Participations of Leaders from top pharma & biopharma companies. The Confex has been well received by both MSMEs and large companies in form of participation and associations. Some of the key participants include companies such as Aurobindo, Dr. Reddy’s. Zydus, Piramal, Wockhardt among others.

Following the Confex, Informa Markets in India is all set to bring in the 5th edition of India Packaging Awards, as a Virtual Award this year and continue its legacy of honoring the success journeys of this ever growing industry, in the midst of a global audience. Slated for 3rd September, the virtual stage is all set and eager to felicitate the best from the Pharma Packaging Industry. The Awards platform will comprise presentations, exclusive product launches, along with the awards and recognition ceremony. The product categories include – Packaging Design, Anti Counterfeiting, Integrated Drug Delivery Systems, Sustainable Packaging, R&D, Machinery, Enhance User Experience and Packaging Team of the year.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com

About Informa Markets and our business in India

Informa Markets is owned by Informa PLC, a leading B2B information services group and the largest B2B Events organiser in the world. Informa Markets in India (formerly UBM India) is India’s leading exhibition organizer, dedicated to help specialist markets and customer communities, domestically and around the world to trade, innovate and grow through exhibitions, digital content & services, and conferences & seminars. Every year, we hosts over 25 large scale exhibitions, 40 conferences, along with industry awards and trainings across the country; thereby enabling trade across multiple industry verticals. In India, Informa Markets has offices across Mumbai, New Delhi, Bangalore and Chennai. For further details, please visit – www.informa.com

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Optimizing Pouch Closure Performance through Advanced Sealant Layer Design

The pharmaceutical industry relies heavily on the physical integrity...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »